Person

Bruce Booth

Bruce Booth is a partner of Atlas Venture and focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. Bruce has been instrumental in forming unique, innovative, and capital efficient structures for drug discovery and development. He co-founded miRagen Therapeutics and Nimbus Therapeutics, and served as acting chief executive officer of Nimbus while incubated at Atlas Venture’s offices. Bruce is chairman of Padlock Therapeutics, where he was a founding investor. Together with Peter Barrett, Bruce seeded and incubated Zafgen (NASDAQ: ZFGN), and identified and facilitated the successful in-licensing of the lead drug program. In addition to these companies, he currently serves as chairman of both Quartet Medicine and Rodin Therapeutics, and also serves on the boards of Lysosomal Therapeutics Inc. (LTI), Numerate, and Unum. Bruce was previously on the boards of past Atlas companies Avila Therapeutics (acquired by Celgene), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), and Proprius (acquired by Cypress Biosciences).

Investors:

Website: http://www.atlasventure.com/

Email: